nodes	percent_of_prediction	percent_of_DWPC	metapath
Conjugated Estrogens—ABCC11—Methotrexate—lymphatic system cancer	0.123	0.144	CbGbCtD
Conjugated Estrogens—SLCO3A1—Methotrexate—lymphatic system cancer	0.0844	0.0992	CbGbCtD
Conjugated Estrogens—ABCC3—Vincristine—lymphatic system cancer	0.056	0.0658	CbGbCtD
Conjugated Estrogens—SLCO1C1—Methotrexate—lymphatic system cancer	0.0539	0.0634	CbGbCtD
Conjugated Estrogens—ABCC1—Mitoxantrone—lymphatic system cancer	0.05	0.0587	CbGbCtD
Conjugated Estrogens—ABCG2—Teniposide—lymphatic system cancer	0.0478	0.0562	CbGbCtD
Conjugated Estrogens—ABCC1—Vincristine—lymphatic system cancer	0.0344	0.0404	CbGbCtD
Conjugated Estrogens—ABCC3—Methotrexate—lymphatic system cancer	0.0339	0.0399	CbGbCtD
Conjugated Estrogens—ABCG2—Mitoxantrone—lymphatic system cancer	0.0335	0.0393	CbGbCtD
Conjugated Estrogens—SLCO1B3—Methotrexate—lymphatic system cancer	0.0301	0.0354	CbGbCtD
Conjugated Estrogens—CYP1A2—Carmustine—lymphatic system cancer	0.0293	0.0345	CbGbCtD
Conjugated Estrogens—SLC22A11—Methotrexate—lymphatic system cancer	0.0278	0.0327	CbGbCtD
Conjugated Estrogens—ABCC4—Methotrexate—lymphatic system cancer	0.0259	0.0305	CbGbCtD
Conjugated Estrogens—ABCC2—Vincristine—lymphatic system cancer	0.0255	0.0299	CbGbCtD
Conjugated Estrogens—ABCG2—Vincristine—lymphatic system cancer	0.023	0.0271	CbGbCtD
Conjugated Estrogens—ABCC1—Methotrexate—lymphatic system cancer	0.0208	0.0245	CbGbCtD
Conjugated Estrogens—SLCO1A2—Methotrexate—lymphatic system cancer	0.0186	0.0219	CbGbCtD
Conjugated Estrogens—SLCO1B1—Methotrexate—lymphatic system cancer	0.0175	0.0206	CbGbCtD
Conjugated Estrogens—SLC22A8—Methotrexate—lymphatic system cancer	0.0162	0.019	CbGbCtD
Conjugated Estrogens—ABCC2—Methotrexate—lymphatic system cancer	0.0154	0.0181	CbGbCtD
Conjugated Estrogens—ABCG2—Methotrexate—lymphatic system cancer	0.0139	0.0164	CbGbCtD
Conjugated Estrogens—ABCB1—Mitoxantrone—lymphatic system cancer	0.0121	0.0142	CbGbCtD
Conjugated Estrogens—SLC22A6—Methotrexate—lymphatic system cancer	0.0113	0.0133	CbGbCtD
Conjugated Estrogens—CYP3A4—Cytarabine—lymphatic system cancer	0.0105	0.0123	CbGbCtD
Conjugated Estrogens—CYP3A4—Teniposide—lymphatic system cancer	0.0103	0.0121	CbGbCtD
Conjugated Estrogens—ABCB1—Vincristine—lymphatic system cancer	0.0083	0.00975	CbGbCtD
Conjugated Estrogens—CYP3A4—Mitoxantrone—lymphatic system cancer	0.00723	0.00849	CbGbCtD
Conjugated Estrogens—ABCB1—Methotrexate—lymphatic system cancer	0.00503	0.00591	CbGbCtD
Conjugated Estrogens—CYP3A4—Vincristine—lymphatic system cancer	0.00497	0.00584	CbGbCtD
Conjugated Estrogens—Oedema peripheral—Carmustine—lymphatic system cancer	0.000312	0.00209	CcSEcCtD
Conjugated Estrogens—Dyspepsia—Fludarabine—lymphatic system cancer	0.000309	0.00208	CcSEcCtD
Conjugated Estrogens—Ulcer—Methotrexate—lymphatic system cancer	0.000309	0.00207	CcSEcCtD
Conjugated Estrogens—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000308	0.00206	CcSEcCtD
Conjugated Estrogens—Decreased appetite—Fludarabine—lymphatic system cancer	0.000306	0.00205	CcSEcCtD
Conjugated Estrogens—Visual impairment—Carmustine—lymphatic system cancer	0.000305	0.00205	CcSEcCtD
Conjugated Estrogens—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000303	0.00204	CcSEcCtD
Conjugated Estrogens—Fatigue—Fludarabine—lymphatic system cancer	0.000303	0.00203	CcSEcCtD
Conjugated Estrogens—Inflammation—Methotrexate—lymphatic system cancer	0.000301	0.00202	CcSEcCtD
Conjugated Estrogens—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000301	0.00202	CcSEcCtD
Conjugated Estrogens—Pain—Fludarabine—lymphatic system cancer	0.000301	0.00202	CcSEcCtD
Conjugated Estrogens—Constipation—Fludarabine—lymphatic system cancer	0.000301	0.00202	CcSEcCtD
Conjugated Estrogens—Eye disorder—Carmustine—lymphatic system cancer	0.000296	0.00198	CcSEcCtD
Conjugated Estrogens—Rhinitis—Mitoxantrone—lymphatic system cancer	0.000295	0.00198	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Teniposide—lymphatic system cancer	0.000295	0.00198	CcSEcCtD
Conjugated Estrogens—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000292	0.00196	CcSEcCtD
Conjugated Estrogens—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000292	0.00196	CcSEcCtD
Conjugated Estrogens—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000292	0.00196	CcSEcCtD
Conjugated Estrogens—Asthenia—Teniposide—lymphatic system cancer	0.000287	0.00192	CcSEcCtD
Conjugated Estrogens—Cystitis noninfective—Methotrexate—lymphatic system cancer	0.000285	0.00191	CcSEcCtD
Conjugated Estrogens—Pruritus—Teniposide—lymphatic system cancer	0.000283	0.0019	CcSEcCtD
Conjugated Estrogens—Arrhythmia—Carmustine—lymphatic system cancer	0.000283	0.0019	CcSEcCtD
Conjugated Estrogens—Cystitis—Methotrexate—lymphatic system cancer	0.000282	0.00189	CcSEcCtD
Conjugated Estrogens—Cardiac disorder—Vincristine—lymphatic system cancer	0.000281	0.00188	CcSEcCtD
Conjugated Estrogens—Alopecia—Carmustine—lymphatic system cancer	0.00028	0.00188	CcSEcCtD
Conjugated Estrogens—Body temperature increased—Fludarabine—lymphatic system cancer	0.000278	0.00186	CcSEcCtD
Conjugated Estrogens—Mental disorder—Carmustine—lymphatic system cancer	0.000277	0.00186	CcSEcCtD
Conjugated Estrogens—Vaginal infection—Methotrexate—lymphatic system cancer	0.000276	0.00185	CcSEcCtD
Conjugated Estrogens—Erythema—Carmustine—lymphatic system cancer	0.000276	0.00185	CcSEcCtD
Conjugated Estrogens—Malnutrition—Carmustine—lymphatic system cancer	0.000276	0.00185	CcSEcCtD
Conjugated Estrogens—Cough—Bleomycin—lymphatic system cancer	0.000276	0.00185	CcSEcCtD
Conjugated Estrogens—Angiopathy—Vincristine—lymphatic system cancer	0.000274	0.00184	CcSEcCtD
Conjugated Estrogens—Diarrhoea—Teniposide—lymphatic system cancer	0.000274	0.00184	CcSEcCtD
Conjugated Estrogens—Mediastinal disorder—Vincristine—lymphatic system cancer	0.000272	0.00183	CcSEcCtD
Conjugated Estrogens—Chest pain—Bleomycin—lymphatic system cancer	0.000269	0.0018	CcSEcCtD
Conjugated Estrogens—Myalgia—Bleomycin—lymphatic system cancer	0.000269	0.0018	CcSEcCtD
Conjugated Estrogens—Alopecia—Vincristine—lymphatic system cancer	0.000267	0.00179	CcSEcCtD
Conjugated Estrogens—Back pain—Carmustine—lymphatic system cancer	0.000267	0.00179	CcSEcCtD
Conjugated Estrogens—Mental disorder—Vincristine—lymphatic system cancer	0.000265	0.00178	CcSEcCtD
Conjugated Estrogens—Bladder pain—Methotrexate—lymphatic system cancer	0.000264	0.00177	CcSEcCtD
Conjugated Estrogens—Neoplasm—Methotrexate—lymphatic system cancer	0.000264	0.00177	CcSEcCtD
Conjugated Estrogens—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.000263	0.00176	CcSEcCtD
Conjugated Estrogens—Alopecia—Mitoxantrone—lymphatic system cancer	0.00026	0.00174	CcSEcCtD
Conjugated Estrogens—Vision blurred—Carmustine—lymphatic system cancer	0.00026	0.00174	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000259	0.00174	CcSEcCtD
Conjugated Estrogens—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.000258	0.00173	CcSEcCtD
Conjugated Estrogens—Oedema—Bleomycin—lymphatic system cancer	0.000258	0.00173	CcSEcCtD
Conjugated Estrogens—Erythema—Mitoxantrone—lymphatic system cancer	0.000256	0.00172	CcSEcCtD
Conjugated Estrogens—Infection—Bleomycin—lymphatic system cancer	0.000256	0.00172	CcSEcCtD
Conjugated Estrogens—Back pain—Vincristine—lymphatic system cancer	0.000255	0.00171	CcSEcCtD
Conjugated Estrogens—Vomiting—Teniposide—lymphatic system cancer	0.000254	0.00171	CcSEcCtD
Conjugated Estrogens—Sepsis—Methotrexate—lymphatic system cancer	0.000253	0.0017	CcSEcCtD
Conjugated Estrogens—Asthenia—Fludarabine—lymphatic system cancer	0.000252	0.00169	CcSEcCtD
Conjugated Estrogens—Rash—Teniposide—lymphatic system cancer	0.000252	0.00169	CcSEcCtD
Conjugated Estrogens—Dermatitis—Teniposide—lymphatic system cancer	0.000252	0.00169	CcSEcCtD
Conjugated Estrogens—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000251	0.00168	CcSEcCtD
Conjugated Estrogens—Headache—Teniposide—lymphatic system cancer	0.000251	0.00168	CcSEcCtD
Conjugated Estrogens—Pruritus—Fludarabine—lymphatic system cancer	0.000249	0.00167	CcSEcCtD
Conjugated Estrogens—Back pain—Mitoxantrone—lymphatic system cancer	0.000248	0.00166	CcSEcCtD
Conjugated Estrogens—Anorexia—Bleomycin—lymphatic system cancer	0.000246	0.00165	CcSEcCtD
Conjugated Estrogens—Thrombophlebitis—Methotrexate—lymphatic system cancer	0.000245	0.00164	CcSEcCtD
Conjugated Estrogens—Vision blurred—Mitoxantrone—lymphatic system cancer	0.000242	0.00162	CcSEcCtD
Conjugated Estrogens—Hypotension—Bleomycin—lymphatic system cancer	0.000241	0.00162	CcSEcCtD
Conjugated Estrogens—Diarrhoea—Fludarabine—lymphatic system cancer	0.000241	0.00161	CcSEcCtD
Conjugated Estrogens—Convulsion—Carmustine—lymphatic system cancer	0.000239	0.0016	CcSEcCtD
Conjugated Estrogens—Nausea—Teniposide—lymphatic system cancer	0.000238	0.00159	CcSEcCtD
Conjugated Estrogens—Vertigo—Vincristine—lymphatic system cancer	0.000236	0.00159	CcSEcCtD
Conjugated Estrogens—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000235	0.00158	CcSEcCtD
Conjugated Estrogens—Myalgia—Carmustine—lymphatic system cancer	0.000235	0.00157	CcSEcCtD
Conjugated Estrogens—Chest pain—Carmustine—lymphatic system cancer	0.000235	0.00157	CcSEcCtD
Conjugated Estrogens—Anxiety—Carmustine—lymphatic system cancer	0.000234	0.00157	CcSEcCtD
Conjugated Estrogens—Paraesthesia—Bleomycin—lymphatic system cancer	0.000231	0.00155	CcSEcCtD
Conjugated Estrogens—Dyspnoea—Bleomycin—lymphatic system cancer	0.00023	0.00154	CcSEcCtD
Conjugated Estrogens—Renal failure acute—Methotrexate—lymphatic system cancer	0.00023	0.00154	CcSEcCtD
Conjugated Estrogens—Convulsion—Vincristine—lymphatic system cancer	0.000228	0.00153	CcSEcCtD
Conjugated Estrogens—Oedema—Carmustine—lymphatic system cancer	0.000225	0.00151	CcSEcCtD
Conjugated Estrogens—Decreased appetite—Bleomycin—lymphatic system cancer	0.000224	0.0015	CcSEcCtD
Conjugated Estrogens—Myalgia—Vincristine—lymphatic system cancer	0.000224	0.0015	CcSEcCtD
Conjugated Estrogens—Visual disturbance—Methotrexate—lymphatic system cancer	0.000224	0.0015	CcSEcCtD
Conjugated Estrogens—Cough—Mitoxantrone—lymphatic system cancer	0.000224	0.0015	CcSEcCtD
Conjugated Estrogens—Infection—Carmustine—lymphatic system cancer	0.000224	0.0015	CcSEcCtD
Conjugated Estrogens—Vomiting—Fludarabine—lymphatic system cancer	0.000224	0.0015	CcSEcCtD
Conjugated Estrogens—Convulsion—Mitoxantrone—lymphatic system cancer	0.000222	0.00149	CcSEcCtD
Conjugated Estrogens—Rash—Fludarabine—lymphatic system cancer	0.000222	0.00149	CcSEcCtD
Conjugated Estrogens—Dermatitis—Fludarabine—lymphatic system cancer	0.000221	0.00149	CcSEcCtD
Conjugated Estrogens—Pain—Bleomycin—lymphatic system cancer	0.00022	0.00148	CcSEcCtD
Conjugated Estrogens—Headache—Fludarabine—lymphatic system cancer	0.00022	0.00148	CcSEcCtD
Conjugated Estrogens—Tachycardia—Carmustine—lymphatic system cancer	0.00022	0.00147	CcSEcCtD
Conjugated Estrogens—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.000219	0.00147	CcSEcCtD
Conjugated Estrogens—Myalgia—Mitoxantrone—lymphatic system cancer	0.000218	0.00146	CcSEcCtD
Conjugated Estrogens—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000218	0.00146	CcSEcCtD
Conjugated Estrogens—Chest pain—Mitoxantrone—lymphatic system cancer	0.000218	0.00146	CcSEcCtD
Conjugated Estrogens—Anxiety—Mitoxantrone—lymphatic system cancer	0.000217	0.00146	CcSEcCtD
Conjugated Estrogens—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000216	0.00145	CcSEcCtD
Conjugated Estrogens—Oedema—Vincristine—lymphatic system cancer	0.000215	0.00144	CcSEcCtD
Conjugated Estrogens—Anaphylactic shock—Vincristine—lymphatic system cancer	0.000215	0.00144	CcSEcCtD
Conjugated Estrogens—Anorexia—Carmustine—lymphatic system cancer	0.000214	0.00144	CcSEcCtD
Conjugated Estrogens—Infection—Vincristine—lymphatic system cancer	0.000213	0.00143	CcSEcCtD
Conjugated Estrogens—Nervous system disorder—Vincristine—lymphatic system cancer	0.000211	0.00141	CcSEcCtD
Conjugated Estrogens—Hypotension—Carmustine—lymphatic system cancer	0.00021	0.00141	CcSEcCtD
Conjugated Estrogens—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.000209	0.0014	CcSEcCtD
Conjugated Estrogens—Oedema—Mitoxantrone—lymphatic system cancer	0.000209	0.0014	CcSEcCtD
Conjugated Estrogens—Nausea—Fludarabine—lymphatic system cancer	0.000209	0.0014	CcSEcCtD
Conjugated Estrogens—Infection—Mitoxantrone—lymphatic system cancer	0.000208	0.00139	CcSEcCtD
Conjugated Estrogens—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000208	0.00139	CcSEcCtD
Conjugated Estrogens—Shock—Mitoxantrone—lymphatic system cancer	0.000206	0.00138	CcSEcCtD
Conjugated Estrogens—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000205	0.00137	CcSEcCtD
Conjugated Estrogens—Urticaria—Bleomycin—lymphatic system cancer	0.000205	0.00137	CcSEcCtD
Conjugated Estrogens—Anorexia—Vincristine—lymphatic system cancer	0.000205	0.00137	CcSEcCtD
Conjugated Estrogens—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000204	0.00137	CcSEcCtD
Conjugated Estrogens—Body temperature increased—Bleomycin—lymphatic system cancer	0.000204	0.00137	CcSEcCtD
Conjugated Estrogens—Insomnia—Carmustine—lymphatic system cancer	0.000203	0.00136	CcSEcCtD
Conjugated Estrogens—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000203	0.00136	CcSEcCtD
Conjugated Estrogens—Irritability—Methotrexate—lymphatic system cancer	0.000202	0.00136	CcSEcCtD
Conjugated Estrogens—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000202	0.00136	CcSEcCtD
Conjugated Estrogens—Paraesthesia—Carmustine—lymphatic system cancer	0.000202	0.00135	CcSEcCtD
Conjugated Estrogens—Mood swings—Methotrexate—lymphatic system cancer	0.000201	0.00135	CcSEcCtD
Conjugated Estrogens—Hypotension—Vincristine—lymphatic system cancer	0.000201	0.00135	CcSEcCtD
Conjugated Estrogens—Dyspnoea—Carmustine—lymphatic system cancer	0.000201	0.00135	CcSEcCtD
Conjugated Estrogens—Somnolence—Carmustine—lymphatic system cancer	0.0002	0.00134	CcSEcCtD
Conjugated Estrogens—Anorexia—Mitoxantrone—lymphatic system cancer	0.000199	0.00134	CcSEcCtD
Conjugated Estrogens—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000196	0.00131	CcSEcCtD
Conjugated Estrogens—Decreased appetite—Carmustine—lymphatic system cancer	0.000196	0.00131	CcSEcCtD
Conjugated Estrogens—Hypotension—Mitoxantrone—lymphatic system cancer	0.000195	0.00131	CcSEcCtD
Conjugated Estrogens—Insomnia—Vincristine—lymphatic system cancer	0.000194	0.0013	CcSEcCtD
Conjugated Estrogens—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000194	0.0013	CcSEcCtD
Conjugated Estrogens—Paraesthesia—Vincristine—lymphatic system cancer	0.000193	0.00129	CcSEcCtD
Conjugated Estrogens—Pain—Carmustine—lymphatic system cancer	0.000192	0.00129	CcSEcCtD
Conjugated Estrogens—Constipation—Carmustine—lymphatic system cancer	0.000192	0.00129	CcSEcCtD
Conjugated Estrogens—Breast disorder—Methotrexate—lymphatic system cancer	0.000192	0.00129	CcSEcCtD
Conjugated Estrogens—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000191	0.00128	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00019	0.00127	CcSEcCtD
Conjugated Estrogens—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000188	0.00126	CcSEcCtD
Conjugated Estrogens—Decreased appetite—Vincristine—lymphatic system cancer	0.000187	0.00125	CcSEcCtD
Conjugated Estrogens—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000186	0.00125	CcSEcCtD
Conjugated Estrogens—Somnolence—Mitoxantrone—lymphatic system cancer	0.000186	0.00125	CcSEcCtD
Conjugated Estrogens—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000185	0.00124	CcSEcCtD
Conjugated Estrogens—Fatigue—Vincristine—lymphatic system cancer	0.000185	0.00124	CcSEcCtD
Conjugated Estrogens—Asthenia—Bleomycin—lymphatic system cancer	0.000185	0.00124	CcSEcCtD
Conjugated Estrogens—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000184	0.00123	CcSEcCtD
Conjugated Estrogens—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000184	0.00123	CcSEcCtD
Conjugated Estrogens—Pain—Vincristine—lymphatic system cancer	0.000184	0.00123	CcSEcCtD
Conjugated Estrogens—Constipation—Vincristine—lymphatic system cancer	0.000184	0.00123	CcSEcCtD
Conjugated Estrogens—Asthma—Methotrexate—lymphatic system cancer	0.000183	0.00123	CcSEcCtD
Conjugated Estrogens—Pruritus—Bleomycin—lymphatic system cancer	0.000182	0.00122	CcSEcCtD
Conjugated Estrogens—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000182	0.00122	CcSEcCtD
Conjugated Estrogens—Fatigue—Mitoxantrone—lymphatic system cancer	0.00018	0.00121	CcSEcCtD
Conjugated Estrogens—Pancreatitis—Methotrexate—lymphatic system cancer	0.00018	0.00121	CcSEcCtD
Conjugated Estrogens—Pain—Mitoxantrone—lymphatic system cancer	0.000179	0.0012	CcSEcCtD
Conjugated Estrogens—Constipation—Mitoxantrone—lymphatic system cancer	0.000179	0.0012	CcSEcCtD
Conjugated Estrogens—Abdominal pain—Carmustine—lymphatic system cancer	0.000178	0.00119	CcSEcCtD
Conjugated Estrogens—Body temperature increased—Carmustine—lymphatic system cancer	0.000178	0.00119	CcSEcCtD
Conjugated Estrogens—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000176	0.00118	CcSEcCtD
Conjugated Estrogens—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000176	0.00118	CcSEcCtD
Conjugated Estrogens—Dysuria—Methotrexate—lymphatic system cancer	0.000171	0.00115	CcSEcCtD
Conjugated Estrogens—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000171	0.00115	CcSEcCtD
Conjugated Estrogens—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00017	0.00114	CcSEcCtD
Conjugated Estrogens—Abdominal pain—Vincristine—lymphatic system cancer	0.00017	0.00114	CcSEcCtD
Conjugated Estrogens—Body temperature increased—Vincristine—lymphatic system cancer	0.00017	0.00114	CcSEcCtD
Conjugated Estrogens—Urticaria—Mitoxantrone—lymphatic system cancer	0.000166	0.00111	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Carmustine—lymphatic system cancer	0.000166	0.00111	CcSEcCtD
Conjugated Estrogens—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000165	0.00111	CcSEcCtD
Conjugated Estrogens—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.000165	0.00111	CcSEcCtD
Conjugated Estrogens—Vomiting—Bleomycin—lymphatic system cancer	0.000164	0.0011	CcSEcCtD
Conjugated Estrogens—Infestation NOS—Methotrexate—lymphatic system cancer	0.000163	0.0011	CcSEcCtD
Conjugated Estrogens—Infestation—Methotrexate—lymphatic system cancer	0.000163	0.0011	CcSEcCtD
Conjugated Estrogens—Depression—Methotrexate—lymphatic system cancer	0.000163	0.00109	CcSEcCtD
Conjugated Estrogens—Rash—Bleomycin—lymphatic system cancer	0.000163	0.00109	CcSEcCtD
Conjugated Estrogens—Dermatitis—Bleomycin—lymphatic system cancer	0.000162	0.00109	CcSEcCtD
Conjugated Estrogens—Asthenia—Carmustine—lymphatic system cancer	0.000161	0.00108	CcSEcCtD
Conjugated Estrogens—Renal failure—Methotrexate—lymphatic system cancer	0.000161	0.00108	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Vincristine—lymphatic system cancer	0.000158	0.00106	CcSEcCtD
Conjugated Estrogens—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000155	0.00104	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000154	0.00103	CcSEcCtD
Conjugated Estrogens—Asthenia—Vincristine—lymphatic system cancer	0.000154	0.00103	CcSEcCtD
Conjugated Estrogens—Diarrhoea—Carmustine—lymphatic system cancer	0.000154	0.00103	CcSEcCtD
Conjugated Estrogens—Nausea—Bleomycin—lymphatic system cancer	0.000153	0.00103	CcSEcCtD
Conjugated Estrogens—Asthenia—Mitoxantrone—lymphatic system cancer	0.00015	0.00101	CcSEcCtD
Conjugated Estrogens—Dizziness—Carmustine—lymphatic system cancer	0.000149	0.000998	CcSEcCtD
Conjugated Estrogens—Diarrhoea—Vincristine—lymphatic system cancer	0.000147	0.000986	CcSEcCtD
Conjugated Estrogens—Pharyngitis—Methotrexate—lymphatic system cancer	0.000146	0.000976	CcSEcCtD
Conjugated Estrogens—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000143	0.00096	CcSEcCtD
Conjugated Estrogens—Vomiting—Carmustine—lymphatic system cancer	0.000143	0.000959	CcSEcCtD
Conjugated Estrogens—Dizziness—Vincristine—lymphatic system cancer	0.000142	0.000953	CcSEcCtD
Conjugated Estrogens—Rash—Carmustine—lymphatic system cancer	0.000142	0.000951	CcSEcCtD
Conjugated Estrogens—Dermatitis—Carmustine—lymphatic system cancer	0.000142	0.000951	CcSEcCtD
Conjugated Estrogens—Visual impairment—Methotrexate—lymphatic system cancer	0.000141	0.000948	CcSEcCtD
Conjugated Estrogens—Headache—Carmustine—lymphatic system cancer	0.000141	0.000945	CcSEcCtD
Conjugated Estrogens—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000139	0.00093	CcSEcCtD
Conjugated Estrogens—Eye disorder—Methotrexate—lymphatic system cancer	0.000137	0.000919	CcSEcCtD
Conjugated Estrogens—Vomiting—Vincristine—lymphatic system cancer	0.000137	0.000916	CcSEcCtD
Conjugated Estrogens—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000136	0.000913	CcSEcCtD
Conjugated Estrogens—Rash—Vincristine—lymphatic system cancer	0.000135	0.000908	CcSEcCtD
Conjugated Estrogens—Dermatitis—Vincristine—lymphatic system cancer	0.000135	0.000907	CcSEcCtD
Conjugated Estrogens—Headache—Vincristine—lymphatic system cancer	0.000135	0.000902	CcSEcCtD
Conjugated Estrogens—Nausea—Carmustine—lymphatic system cancer	0.000134	0.000896	CcSEcCtD
Conjugated Estrogens—Angiopathy—Methotrexate—lymphatic system cancer	0.000133	0.000893	CcSEcCtD
Conjugated Estrogens—Vomiting—Mitoxantrone—lymphatic system cancer	0.000133	0.000892	CcSEcCtD
Conjugated Estrogens—Immune system disorder—Methotrexate—lymphatic system cancer	0.000132	0.000889	CcSEcCtD
Conjugated Estrogens—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000132	0.000887	CcSEcCtD
Conjugated Estrogens—Rash—Mitoxantrone—lymphatic system cancer	0.000132	0.000885	CcSEcCtD
Conjugated Estrogens—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000132	0.000884	CcSEcCtD
Conjugated Estrogens—Headache—Mitoxantrone—lymphatic system cancer	0.000131	0.000879	CcSEcCtD
Conjugated Estrogens—Alopecia—Methotrexate—lymphatic system cancer	0.00013	0.000869	CcSEcCtD
Conjugated Estrogens—Mental disorder—Methotrexate—lymphatic system cancer	0.000128	0.000862	CcSEcCtD
Conjugated Estrogens—Malnutrition—Methotrexate—lymphatic system cancer	0.000128	0.000856	CcSEcCtD
Conjugated Estrogens—Erythema—Methotrexate—lymphatic system cancer	0.000128	0.000856	CcSEcCtD
Conjugated Estrogens—Nausea—Vincristine—lymphatic system cancer	0.000128	0.000856	CcSEcCtD
Conjugated Estrogens—Dysgeusia—Methotrexate—lymphatic system cancer	0.000125	0.000839	CcSEcCtD
Conjugated Estrogens—Nausea—Mitoxantrone—lymphatic system cancer	0.000124	0.000833	CcSEcCtD
Conjugated Estrogens—Back pain—Methotrexate—lymphatic system cancer	0.000124	0.000828	CcSEcCtD
Conjugated Estrogens—Vision blurred—Methotrexate—lymphatic system cancer	0.00012	0.000807	CcSEcCtD
Conjugated Estrogens—Vertigo—Methotrexate—lymphatic system cancer	0.000115	0.000769	CcSEcCtD
Conjugated Estrogens—Cough—Methotrexate—lymphatic system cancer	0.000111	0.000747	CcSEcCtD
Conjugated Estrogens—Convulsion—Methotrexate—lymphatic system cancer	0.000111	0.000742	CcSEcCtD
Conjugated Estrogens—Arthralgia—Methotrexate—lymphatic system cancer	0.000109	0.000729	CcSEcCtD
Conjugated Estrogens—Chest pain—Methotrexate—lymphatic system cancer	0.000109	0.000729	CcSEcCtD
Conjugated Estrogens—Myalgia—Methotrexate—lymphatic system cancer	0.000109	0.000729	CcSEcCtD
Conjugated Estrogens—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000108	0.000724	CcSEcCtD
Conjugated Estrogens—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000104	0.000699	CcSEcCtD
Conjugated Estrogens—Infection—Methotrexate—lymphatic system cancer	0.000104	0.000694	CcSEcCtD
Conjugated Estrogens—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000102	0.000685	CcSEcCtD
Conjugated Estrogens—Skin disorder—Methotrexate—lymphatic system cancer	0.000101	0.000679	CcSEcCtD
Conjugated Estrogens—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000101	0.000676	CcSEcCtD
Conjugated Estrogens—Anorexia—Methotrexate—lymphatic system cancer	9.93e-05	0.000666	CcSEcCtD
Conjugated Estrogens—Hypotension—Methotrexate—lymphatic system cancer	9.74e-05	0.000653	CcSEcCtD
Conjugated Estrogens—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	9.49e-05	0.000637	CcSEcCtD
Conjugated Estrogens—Insomnia—Methotrexate—lymphatic system cancer	9.42e-05	0.000632	CcSEcCtD
Conjugated Estrogens—Paraesthesia—Methotrexate—lymphatic system cancer	9.36e-05	0.000628	CcSEcCtD
Conjugated Estrogens—Dyspnoea—Methotrexate—lymphatic system cancer	9.29e-05	0.000623	CcSEcCtD
Conjugated Estrogens—Somnolence—Methotrexate—lymphatic system cancer	9.26e-05	0.000621	CcSEcCtD
Conjugated Estrogens—Dyspepsia—Methotrexate—lymphatic system cancer	9.17e-05	0.000615	CcSEcCtD
Conjugated Estrogens—Decreased appetite—Methotrexate—lymphatic system cancer	9.06e-05	0.000608	CcSEcCtD
Conjugated Estrogens—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	9e-05	0.000603	CcSEcCtD
Conjugated Estrogens—Fatigue—Methotrexate—lymphatic system cancer	8.98e-05	0.000603	CcSEcCtD
Conjugated Estrogens—Pain—Methotrexate—lymphatic system cancer	8.91e-05	0.000598	CcSEcCtD
Conjugated Estrogens—Gastrointestinal pain—Methotrexate—lymphatic system cancer	8.52e-05	0.000572	CcSEcCtD
Conjugated Estrogens—Urticaria—Methotrexate—lymphatic system cancer	8.28e-05	0.000555	CcSEcCtD
Conjugated Estrogens—Body temperature increased—Methotrexate—lymphatic system cancer	8.24e-05	0.000553	CcSEcCtD
Conjugated Estrogens—Abdominal pain—Methotrexate—lymphatic system cancer	8.24e-05	0.000553	CcSEcCtD
Conjugated Estrogens—Hypersensitivity—Methotrexate—lymphatic system cancer	7.68e-05	0.000515	CcSEcCtD
Conjugated Estrogens—Asthenia—Methotrexate—lymphatic system cancer	7.48e-05	0.000501	CcSEcCtD
Conjugated Estrogens—Pruritus—Methotrexate—lymphatic system cancer	7.37e-05	0.000495	CcSEcCtD
Conjugated Estrogens—Diarrhoea—Methotrexate—lymphatic system cancer	7.13e-05	0.000478	CcSEcCtD
Conjugated Estrogens—Dizziness—Methotrexate—lymphatic system cancer	6.89e-05	0.000462	CcSEcCtD
Conjugated Estrogens—Vomiting—Methotrexate—lymphatic system cancer	6.63e-05	0.000444	CcSEcCtD
Conjugated Estrogens—Rash—Methotrexate—lymphatic system cancer	6.57e-05	0.000441	CcSEcCtD
Conjugated Estrogens—Dermatitis—Methotrexate—lymphatic system cancer	6.56e-05	0.00044	CcSEcCtD
Conjugated Estrogens—Headache—Methotrexate—lymphatic system cancer	6.53e-05	0.000438	CcSEcCtD
Conjugated Estrogens—Nausea—Methotrexate—lymphatic system cancer	6.19e-05	0.000415	CcSEcCtD
